Search Results - "Burger, Michael C."

Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphoma.

Authors: Walter, Clara Burger, Michael C. Siebenbrodt, Kai et al.

Source: Leukemia & Lymphoma. Jul2026, Vol. 67 Issue 8, p1806-1810. 5p.

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.

Authors: Burger, Michael C. Breuer, Stella Cieplik, Hans C. et al.

Source: International Journal of Molecular Sciences. Nov2017, Vol. 18 Issue 11, p2469. 11p.

Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.

Authors: WENGER, KATHARINA J. BURGER, MICHAEL C. VOSS, MARTIN et al.

Source: Oncology Letters. Jul2017, Vol. 14 Issue 1, p1141-1146. 6p. 2 Charts, 2 Graphs.

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.

Authors: Burger, Michael C. Mildenberger, Iris C. Wagner, Marlies et al.

Source: International Journal of Molecular Sciences. Apr2017, Vol. 18 Issue 4, p726. 10p. 2 Diagrams, 5 Charts, 1 Graph.

Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors.

Authors: Burger, Michael C. Zeiner, Pia S. Jahnke, Kolja et al.

Source: PLoS ONE. 6/2/2016, Vol. 11 Issue 6, p1-10. 10p.

This result is not displayed to guests.
Login for full access.

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.

Authors: Congcong Zhang Burger, Michael C. Jennewein, Lukas et al.

Source: JNCI: Journal of the National Cancer Institute. May2016, Vol. 108 Issue 5, p1-12. 12p. 7 Graphs.

Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases.

Authors: Burger, Michael C. Wagner, Marlies Franz, Kea et al.

Source: Journal of Clinical Medicine. Aug2018, Vol. 7 Issue 8, p216. 1p.

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.

Authors: Ronellenfitsch, Michael W. Brucker, Daniel P. Burger, Michael C. et al.

Source: Brain: A Journal of Neurology; Jun2009, Vol. 132 Issue 6, p1509-1522, 14p, 6 Graphs

Comparative cross-methodological analysis of the IDH-wildtype glioblastoma tumor microenvironment.

Authors: Cakmak, Pinar Lun, Jennifer H. Köhler, Miriam et al.

Source: Journal of Cancer Research & Clinical Oncology. Feb2026, Vol. 152 Issue 2, p1-15. 15p.

Spatial immune profiling defines a subset of human gliomas with functional tertiary lymphoid structures.

Authors: Cakmak, Pinar Lun, Jennifer H. Singh, Aakanksha et al.

Source: Immunity (10747613). Nov2025, Vol. 58 Issue 11, p2847-28286. 25440p.

Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort.

Authors: Rha, Sun Young Castanon, Eduardo Gill, Sanjeev et al.

Source: Cancer (0008543X). Aug2025, Vol. 131 Issue 16, p1-12. 12p.

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial.

Authors: Zeyen, Thomas Potthoff, Anna-Laura Nemeth, Robert et al.

Source: Trials. 5/17/2022, Vol. 23 Issue 1, p1-16. 16p.

Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.

Authors: Genßler, Sabrina Burger, Michael C. Zhang, Congcong et al.

Source: OncoImmunology. 2016, Vol. 5 Issue 4, pN.PAG-N.PAG. 1p.

Non-Invasive Measurement of Drug and 2-HG Signals Using 19 F and 1 H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032.

Authors: Wenger, Katharina J. Richter, Christian Burger, Michael C. et al.

Source: Cancers. Nov2020, Vol. 12 Issue 11, p3175. 1p.

Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma.

Authors: Eriksson, Jule A. Wanka, Christina Burger, Michael C. et al.

Source: Journal of Neurochemistry. Feb2018, Vol. 144 Issue 4, p421-430. 10p.

Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors.

Authors: Harter, Patrick N. Jennewein, Lukas Baumgarten, Peter et al.

Source: PLoS ONE. May2015, Vol. 10 Issue 5, p1-20. 20p.

Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas.

Authors: Divé, Iris Steidl, Eike Wagner, Marlies et al.

Source: Oncology. 2021, Vol. 99 Issue 4, p215-224. 10p.

Calcitriol Promotes Differentiation of Glioma Stem-Like Cells and Increases Their Susceptibility to Temozolomide.

Authors: Gerstmeier, Julia Possmayer, Anna-Lena Bozkurt, Süleyman et al.

Source: Cancers. Jul2021, Vol. 13 Issue 14, p3577. 1p.

Local Anesthetic-Induced Central Nervous System Toxicity during Interscalene Brachial Plexus Block: A Case Series Study of Three Patients.

Authors: Spitzer, Daniel Wenger, Katharina J. Neef, Vanessa et al.

Source: Journal of Clinical Medicine. Mar2021, Vol. 10 Issue 5, p1013-1013. 1p.